Accreditation
An application has been made to the UEMS EACCME for CME accreditation of this event.
An application has been made to the UEMS EACCME for CME accreditation of this event.
THURSDAY, DECEMBER 13, 2018 | 11.00 – 12.30
Does Psoriasis Treatment Alter the Risk of Comorbidities? Examining the Evidence
Symposium supported by Eli Lilly
Chair: Eyerich, Kilian, Munich, Germany
11.00 – 11.10 | Psoriasis and Comorbidities: An Overview Eyerich, Kilian, Munich, Germany |
11.10 – 11.25 | The Role of Cytokines in the Pathogenesis of Psoriasis and Associated Comorbidities Brunner, Patrick, Vienna, Austria |
11.25 – 11.45 | Does Psoriasis Treatment affect Cardiovascular Disease? Joel Gelfand, Philadelphia, PA, USA |
11.45 – 12.05 | Psoriasis and Psyche: What Do We Know? Kristian Reich, Berlin, Germany |
12.05 – 12.25 | Panel Discussion and Audience Q&A: Implications for Psoriasis Management All faculty |
12.25 – 12.30 | Concluding Remarks and Close Eyerich, Kilian, Munich, Germany |
FRIDAY, DECEMBER 14, 2018 | 08.00 – 09.30
Discover the potential: exploring new frontiers of IL-23 inhibitors
Symposium supported by Janssen
Chair: Antonio Costanzo, Milano, Italy & Kilian Eyerich, Munich, Germany
08.30 – 08.35 | Welcome and introduction Antonio Costanzo, Milano, Italy |
08.35 – 08.55 | Advancing the science of psoriasis: the underlying pathology and the role IL-23 Antonio Costanzo, Milano, Italy |
08.55 – 09.15 | New horizons in managing psoriasis: individualizing care one patient at a time Kilian Eyerich, Munich, Germany |
09.15 – 09.25 | Interactive Q&A session Antonio Costanzo, Milano, Italy & Kilian Eyerich, Munich, Germany |
09.25 – 09.30 | Summary and closing Kilian Eyerich, Munich, Germany |
FRIDAY, DECEMBER 14, 2018 | 12.00 – 13.30
THE GREAT DEBATE:
Should the Treatment Paradigm for Mild to Moderate Atopic Dermatitis (AD) Evolve?
Symposium supported by Pfizer
Moderator: Charles Lynde (Ontario, Canada)
Invited Speaker | Aviv Barzilai, Tel Aviv, Israel |
Invited Speaker | Adelaide A. Hebert, Houston, USA |
Invited Speaker | Torsten Zuberbier, Berlin, Germany |
SATURDAY, DECEMBER 15, 2018 | 08.00 – 09.30
Atopic Dermatitis and Beyond: Pathogenic and Therapeutic Advances
Symposium supported by Sanofi
08.00 – 08.10 | Introduction Emma Guttman, New York, USA |
08.10 – 08.35 | Atopic Dermatitis: Emerging as a cytokine-driven disease and novel therapeutic developments Emma Guttman, New York, USA |
08.35 – 08.55 | Pediatric atopic dermatitis–pathogenic and therapeutic advances and implications for the atopic march Patrick Brunner, Vienna, Austria |
08.55 – 09.20 | Th2 Inhibition beyond atopic dermatitis Frank O. Nestle, Boston, USA |
09.20 – 09.30 | Panel Discussion Emma Guttman, Frank O. Nestle, Patrick Brunner |
Reception and Poster Viewing
Wednesday, December 12, 2018
Start: 18:35-21:00
Finger food and drinks will be served
Ticket price: included in registration fee
Official Networking Evening
Thursday, December 13, 2018
Official Networking Evening at Augustinerkeller (Augustinerstraße 1, 1010 Wien)
Ticket price: EUR 30,00
(as per December 11th, 2018)
WEDNESDAY, DECEMBER 12, 2018 |
14.00 | Registration opens |
Opening | Session chairs afternoon: Emma Guttman (New York, USA) Patrick M. Brunner (Vienna, Austria) |
16.00 – 16.10 | Welcome address |
16.10 – 16.35 | Setting the stage – Historic perspectives Georg Stingl (Vienna, Austria) |
16.35 – 17.00 | Setting the stage – The translational revolution in inflammatory skin diseases James G. Krueger (New York, NY, USA) |
17.00 –17.30 | Two sides of Th17 cells in autoimmunity and tissue homeostasis Vijay Kuchroo (Boston, MA, USA) |
Session chairs evening: |
|
17.30 – 18.30 |
Oral presentations from selected abstracts #125 Selective oral JAK3 and TYK2/JAK1 kinase inhibitors both
#LB4 Guselkumab demonstrates superior long-term responses to secukinumab at Week48 in the treatment of moderate to severe psoriasis: Results from the ECLIPSE trial |
18.30 – 21.00 | Poster viewing and networking |
THURSDAY, DECEMBER 13, 2018 |
Session chairs morning: Sylvia Knapp (Vienna, Austria) Michael Detmar (Zurich, Switzerland) |
|
08.30 – 9.00 | A perspective of dendritic cells in inflammatory skin diseases Thomas Bieber (Bonn, Germany) |
09.00 – 09.30 | Resident T cells in health and disease Rachael Clark (Boston, MA, USA) |
09.30 – 10.00 | T cell subsets across inflammation and cancer Thomas S. Kupper (Boston, MA, USA) |
10.00 – 10.30 | Innate lymphoid cells in health and disease Graham Ogg (Oxford, United Kingdom) |
10.30 – 10.45 | Oral presentations from selected abstracts
#112 Resident T cells trigger disease-associated tissue responses that stratify clinical outcome in human psoriasis. |
10.45 – 11.00 | BREAK |
11.00 – 12.30 | Does Psoriasis Treatment Alter the Risk of Comorbidities? Examining the Evidence Symposium supported by Eli Lilly Chair: Kilian Eyerich (Munich, Germany)Psoriasis and Comorbidities: An Overview Kilian Eyerich (Munich, Germany) The Role of Cytokines in the Pathogenesis of Psoriasis and Associated Comorbidities Does Psoriasis Treatment affect Cardiovascular Disease? Psoriasis and Psyche: What Do We Know? Panel Discussion and Audience Q&A: Implications for Psoriasis Management Concluding Remarks and Close |
12.30 – 13.00 | BREAK |
Session chairs afternoon: |
|
13.00 – 14.00 |
Oral presentations from selected abstracts #138 Blood endotyping distinguishes the profile of vitiligo from other #102 Low-input RNA sequencing reveals survival program of human skin-resident T cells during complete myeloablation. #78 A critical role for IL-37 in regulatory T cell maintenance and CD4+ T cell inhibition. #70 KLK6-PAR1 signaling drives psoriasiform manifestations in skin and bone and blockade of PAR1 in explanted psoriasis patient skin decreases key psoriasis transcripts. |
14.00 – 14.30 | Protective immunity and immunodeficiencies Jean-Laurent Casanova (New York, NY, USA) |
14.30 – 15.30 | COFFEE BREAK |
Session chairs late afternoon: |
|
15.30 – 16.00 | Janus kinases in inflammation Massimo Gadina (Bethesda, MD, USA) on behalf of John O’Shea (Bethesda, MD, USA) |
16.00 – 16.30 | Visualization of skin inflammation and resulting immunologic concepts Kenji Kabashima (Kyoto, Japan) |
16.30– 17.00 | The microbiome and therapeutic implications Richard Gallo (San Diego, CA, USA) |
17.00-17.30 |
Oral presentations from selected abstracts #74 Triple correlation between skin microbiome, skin barrier and immune gene expression pathways in atopic dermatitis. #45 Baseline inflammatory biomarker profiles and clinical heterogeneity of adult patients with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids. |
Official Networking Evening |
FRIDAY, DECEMBER 14, 2018 |
08.00 – 09.30 | Discover the potential: exploring new frontiers of IL-23 inhibitors Symposium supported by Janssen Chair: Antonio Costanzo (Milano, Italy) & Kilian Eyerich (Munich, Germany) Welcome and introduction Advancing the science of psoriasis: the underlying pathology and the role IL-23 New horizons in managing psoriasis: individualizing care one patient at a time Interactive Q&A session Summary and closing |
09.30 – 09.45 | BREAK |
Session chairs morning: Stephan Weidinger (Kiel, Germany) James T. Elder (Ann Arbor, Michigan) |
|
09.45 – 10.15 | How to perform successful clinical trials in inflammatory skin diseases Kristian Reich (Hamburg, Germany) |
10.15 – 10.45 | Framing psoriasis James G. Krueger (New York, NY, USA) |
10.45 – 11.15 | Autoantigens in psoriasis Michel Gilliet (Lausanne, Switzerland) |
11.15 – 11.45 | Impact of immune targeted therapy on cardiovascular risk: The psoriasis model Joel Gelfand (Philadelphia, PA, USA) |
11.45 – 12.00 | BREAK |
12.00 – 13.30 | THE GREAT DEBATE: Should the Treatment Paradigm for Mild to Moderate Atopic Dermatitis (AD) Evolve? Symposium supported by Pfizer Moderator: Charles Lynde (Ontario, Canada) Invited Speaker: Aviv Barzilai (Tel Aviv, Israel) Invited Speaker: Adelaide A. Hebert (Houston,TX, USA) Invited Speaker: Torsten Zuberbier (Berlin, Germany) |
13.30 – 13.45 | BREAK |
Session chairs afternoon: Matthias Schmuth (Innsbruck, Austria) Zuhair Ballas (Iowa City, USA) |
|
13.45 – 14.15 | Inflammatory profile of atopic dermatitis and cytokine targeted treatments Emma Guttman (New York, NY, USA) |
14.15 – 14.45 | Barrier defects in atopic dermatitis and prevention strategies Alan Irvine (Dublin, Ireland) |
14.45 – 15.15 | Atopic dermatitis at disease onset Patrick M. Brunner (Vienna, Austria) |
15.15 – 15.45 | Adopting Orphan Ichthyoses: New Focus for Inflammatory Skin Research Amy S. Paller (Chicago, IL, USA) |
15.45 – 16.15 | COFFEE BREAK |
Session chairs late afternoon: Alain Hovnanian (Paris, France) Tove Agner (Copenhagen, Denmark) |
|
16.15 – 16.45 | Epicutaneous antigen desensitization Christophe Dupont (Paris, France) |
16.45 –17.15 | Peripheral tolerance to autoimmune target in pemphigus Masayuki Amagai (Tokyo, Japan) |
17.15-18.05 |
Oral presentations from selected abstracts #48 Conjunctival inflammation and loss of goblet cells in atopic dermatitis patients treated with dupilumab in daily practice.
#21 Sodium chloride is an ionic checkpoint for human Th2 cell responses and shapes the atopic skin micro environment |
SATURDAY, DECEMBER 15, 2018 |
08.00 – 09.30 | Atopic Dermatitis and Beyond: Pathogenic and Therapeutic Advances Symposium supported by Sanofi Genzyme Introduction Atopic Dermatitis: Emerging as a cytokine-driven disease and novel therapeutic developments Pediatric atopic dermatitis–pathogenic and therapeutic advances and implications for the atopic march Th2 Inhibition beyond atopic dermatitis Panel Discussion |
09.30 – 09.45 | BREAK |
Session chairs morning: |
|
09.45 – 10.00 | Oral presentations from selected abstracts
#120 Massive expansion of drug-specific, clonotypic and polycytotoxic CD8+ T cells in Toxic Epidermal Necrolysis. |
10.00 – 10.30 | Alopecia areata Ralf Paus (Manchester, UK) |
10.30 – 11.00 | Acne & Rosacea Martin Steinhoff (Dublin, Ireland) |
11.00 – 11.30 | Vitiligo John Harris (Worchester, MA, USA) |
11.30 – 12.00 | COFFEE BREAK |
Session chairs afternoon: Peter Wolf (Graz, Austria) Daniel Aletaha (Vienna, Austria) |
|
12.00 – 12.30 | Eosinophilic disorders Bruce Bochner (Chicago, IL, USA) |
12.30 – 13.00 | Adding new pieces to the old Lupus puzzle Virginia Pascual (New York, NY, USA) |
13.00 – 13.30 | Dermatomyositis: Pearls, Pitfalls, and an Evolving Therapeutic Landscape Ruth Ann Vleugels (Boston, MA, USA) |
Session chairs late afternoon: |
|
13.30 – 14.20 |
Oral presentations from selected abstracts #117 Early Improvement in Pruritus and Reduction in Clinical Signs in a Phase 2a Mechanism of Action Study of Crisaborole in Mild to Moderate Atopic Dermatitis.
|
14.20 – 14.30 | Closing session |
Confirmed speakers (as per December 11, 2018):
Masayuki Amagai, Tokyo, Japan – Peripheral tolerance to autoimmune target in pemphigus
Thomas Bieber, Bonn, Germany – Dendritic cells in inflammatory skin diseases
Bruce Bochner, Chicago, IL – Eosinophilic disorders
Patrick M. Brunner, Vienna, Austria – Atopic dermatitis at disease onset
Jean-Laurent Casanova, New York, NY – Protective immunity and immunodeficiencies
Rachael Clark, Boston, MA – Resident T cells in health and disease
Christophe Dupont, Paris, France – Epicutaneous antigen desensitization
Massimo Gadina, Bethesda, MD – Janus kinases in inflammation
Richard Gallo, San Diego, CA – The microbiome and therapeutic implications
Joel Gelfand, Philadelphia, PA – Impact of immune targeted therapy on cardiovascular risk: The psoriasis model
Michel Gilliet, Lausanne, Switzerland – Autoantigens in psoriasis
Emma Guttman, New York, NY – Inflammatory profile of atopic dermatitis and cytokine targeted treatments
John Harris, Worcester, MA – Vitiligo
Alan Irvine, Dublin, Ireland – Barrier defects in AD and prevention strategies
Kenji Kabashima, Kyoto, Japan – Visualization of skin inflammation and resulting immunologic concepts
James G. Krueger, New York, NY – Framing psoriasis
Vijay Kuchroo, Boston, MA – Two sides of Th17 cells in autoimmunity and tissue homeostasis
Thomas Kupper, Boston, MA – T cell subsets across inflammation and cancer
Graham Ogg, Oxford, UK – Innate lymphoid cells in health and disease
Amy S. Paller, Chicago, IL – Adopting orphan ichthyoses: New focus for inflammatory skin research
Virginia Pascual, New York, NY – Adding new pieces to the old Lupus puzzle
Ralf Paus, Manchester, UK – Alopecia areata
Kristian Reich, Hamburg, Germany – How to perform successful clinical trials in inflammatory skin diseases
Martin Steinhoff, Dublin, Ireland – Acne & Rosacea
Georg Stingl, Vienna, Austria – Historic perspective
Ruth Ann Vleugels, Boston, MA – Collagenoses